Factors Associated With Nonprescription of Oseltamivir for Infant Influenza Over 9 Seasons
Journal of the Pediatric Infectious Diseases Society · 2024
DOI: 10.1093/jpids/piae075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2024. Verfasst von Haniah A Zaheer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, UPMC Eye Institute, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Oseltamivir, Influenza, Human, Antiviral Agents, Nonprescription Drugs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, University of Pittsburgh.
Abstract (Originalsprache)
Background
The Centers for Disease Control and Prevention (CDC) recommends oseltamivir phosphate for children <2 years old with confirmed or suspected influenza as they are at high risk for complications. We analyzed infant characteristics associated with nonprescription of oseltamivir over 9 years.
Methods
We conducted a retrospective electronic health record (EHR) review of infants <12 months old born between January 1, 2012 and December 31, 2019 within the University of Pittsburgh Medical Center health system in Southwestern Pennsylvania who had >2 well-child visits during their first year. Infants with a confirmed positive test for influenza were included in the analysis. Factors associated with infant oseltamivir nonprescription were assessed using multivariable logistic regression.
Results
Of 457 infants with confirmed influenza, 86% were prescribed oseltamivir. The proportion of infants prescribed oseltamivir increased from an average of 64.6% during the 2012–2016 influenza seasons to 90.4% during the 2016–2020 influenza seasons. Infants were more likely to not be prescribed oseltamivir if they experienced >2 days of influenza symptoms (odds ratio (OR): 9.4, 95% CI: 4.8, 18.7, P < .001), were diagnosed during the 2012–2016 influenza seasons (OR: 4.2, 95% CI: 1.8, 9.5, P < .001), tested positive for influenza via a multiplex/reverse transcriptase polymerase chain reaction test (OR: 6.7, 95% CI: 2.7, 16.3, P < .001; OR: 2.7, 95% CI: 1.1, 7.1; P = .04), or did not have a fever at point-of-care (OR: 2.3, 95% CI: 1.2, 4.6, P = .01).
Conclusion
Adherence to CDC influenza antiviral treatment guidelines for infants is high and improved over time. However, the provision of targeted education to providers may further improve oseltamivir prescribing practices for high-risk children <12 months of age.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, UPMC Eye Institute, Pittsburgh, Pennsylvania, USA.
- Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- University of Pittsburgh
- NIH HHS
- National Institutes of Health
Zitieren
APA
Zaheer, H. A., Moehling Geffel, K., Chamseddine, S., Liu, H., Williams, J. V., Martin, J. M., & Rick, A. M. (2024). Factors Associated With Nonprescription of Oseltamivir for Infant Influenza Over 9 Seasons. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piae075
Vancouver
Zaheer HA, Moehling Geffel K, Chamseddine S, Liu H, Williams JV, Martin JM, et al. Factors Associated With Nonprescription of Oseltamivir for Infant Influenza Over 9 Seasons. Journal of the Pediatric Infectious Diseases Society. 2024. doi:10.1093/jpids/piae075
BibTeX
@article{Zaheer2024,
author = {Zaheer, Haniah A and Moehling Geffel, Krissy and Chamseddine, Sarah and Liu, Hui and Williams, John V and Martin, Judith M and Rick, Anne-Marie},
title = {Factors Associated With Nonprescription of Oseltamivir for Infant Influenza Over 9 Seasons},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2024},
doi = {10.1093/jpids/piae075}
}
EUVIMED